Abstract
Overview
Introduction
Despite several developments in efforts to tackle the spread of HIV, the total
number of people living with HIV has continued to increase across the 6MM.
However, significant advances in HIV disease understanding, treatment and
management mean that the outlook for patients has considerably improved.
Scope
- Current epidemiology of HIV in the six major markets, including
prevalence, diagnosis rates and patients split by line of therapy and drug
regimens
- A detailed examination of the patient numbers on each line of therapy,
their drug regimens and preferences
- Evaluation of the factors determining prescription choices and their
respective level of influence
- An assessment of the perception of new products in development and of key
unmet needs within HIV
Highlights
In the US and M5EU the total number of people living with HIV is continuing to
increase. According to Datamonitor' s physician survey, the total number of
diagnosed patients across the 6MM is 1.1 million, of which 18% are
treatment-naïve and approx. 800.000 are currently receiving therapy
The complexity of HAART begins to increase as patients progress to later
stages of therapy, with regimens consisting of up to 6 different drugs.
Treatment also becomes much more individualized: Datamonitor' s research shows
that the top 5 most popular regimens selected by physicians account for only
13% of patients in salvage therapy
Prescription choice is largely driven by patient and product-specific
qualities, but the influence of these issues varies according to line of
therapy. Efficacy and resistance profile exert an increasing influence as the
patient becomes more treatment-experienced.
Reasons to Purchase
- Identify the key factors underlying prescription choice for treatment of
HIV
- Examine the current unmet needs in the HIV market and identify
opportunities for new product development
- Enhance your commercial positioning through an improved understanding of
the HIV market dynamics
View Cart
